Severe, chronic eye allergy is an understudied, vision-threatening condition. Treatments remain limited. We used a mouse model of severe allergic eye disease (AED) to determine whether topical application of the pro-resolution mediator Resolvin D1 (RvD1) terminates the response. AED was induced by injection of ovalbumin (OVA) followed by topical challenge of OVA daily. RvD1 was applied topically prior to OVA. Clinical symptoms were scored. Eye washes were assayed for MUC5AC. After 7 days, eyes were removed and the number of goblet cells, T helper cell responses and presence of immune cells in draining lymph nodes and conjunctiva determined. Topical RvD1 treatment significantly reduced symptoms of AED. RvD1 did not alter the systemic type 2 immune response in the lymph nodes. AED increased the total amount of goblet cell mucin secretion, but not the number of goblet cells. RvD1 prevented this increase, but did not alter goblet cell number. Absolute numbers of CD4 + T cells, total CD11b + myeloid cells, eosinophils, neutrophils, and monocytes, but not macrophages increased in AED versus RvD1-treated mice. We conclude that topical application of RvD1 reduced the ocular allergic response by local actions in conjunctival immune response and a decrease in goblet cell mucin secretion.

中文翻译：

---

Resolvin D1 治疗杯状细胞粘蛋白和慢性过敏性眼病 (AED) 模型中的免疫反应。

严重的慢性眼睛过敏是一种未被充分研究的威胁视力的疾病。治疗仍然有限。我们使用严重过敏性眼病 (AED) 的小鼠模型来确定促分辨率调解剂 Resolvin D1 (RvD1) 的局部应用是否会终止反应。AED 是通过注射卵清蛋白 (OVA) 然后每天局部攻击 OVA 来诱导的。RvD1 在 OVA 之前局部应用。对临床症状进行评分。对洗眼液进行 MUC5AC 测定。7 天后，取出眼睛并测定杯状细胞的数量、T 辅助细胞反应以及引流淋巴结和结膜中免疫细胞的存在。外用 RvD1 治疗显着减轻了 AED 的症状。RvD1 没有改变淋巴结中的全身 2 型免疫反应。AED增加杯状细胞粘蛋白分泌总量，但不是杯状细胞的数量。RvD1 阻止了这种增加，但没有改变杯状细胞的数量。CD4 + T 细胞的绝对数量、CD11b + 骨髓细胞总数、嗜酸性粒细胞、嗜中性粒细胞和单核细胞的绝对数量增加，但巨噬细胞在 AED 与 RvD1 处理的小鼠中没有增加。我们得出结论，RvD1 的局部应用通过结膜免疫反应的局部作用和杯状细胞粘蛋白分泌的减少减少了眼部过敏反应。